UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical and economic burden of infused iron chelation therapy in the United States

Transfusion (Philadelphia, Pa.), 2007-10, Vol.47 (10), p.1820-1829

2007

Volltextzugriff (PDF)

Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload

Advances in therapy, 2008-08, Vol.25 (8), p.725-742

2008

Volltextzugriff (PDF)

Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review

Transfusion (Philadelphia, Pa.), 2007-10, Vol.47 (10), p.1919-1929

2007

Volltextzugriff (PDF)

Use of economic evaluation guidelines: 2 years' experience in Canada

Health economics, 1998-05, Vol.7 (3), p.221-227

1998

Volltextzugriff (PDF)

The impact of iron overload and its treatment on quality of life: results from a literature review

Health and quality of life outcomes, 2006-09, Vol.4 (1), p.73-73, Article 73

2006

Volltextzugriff (PDF)

Satisfaction and Adherence in Patients with Iron Overload Receiving Iron Chelation Therapy as Assessed by a Newly Developed Patient Instrument

Value in health, 2009, Vol.12 (1), p.109-117

2009

Volltextzugriff (PDF)

Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib

Value in health, 2011-09, Vol.14 (6), p.846-851

2011

Volltextzugriff (PDF)

Satisfaction and Adherence Significantly Improves in Patients with β-Thalassemia and Myelodysplastic Syndromes Treated with Deferasirox (Exjade®)

Blood, 2008-11, Vol.112 (11), p.1306-1306

2008

Volltextzugriff (PDF)

Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade®)

Blood, 2008-11, Vol.112 (11), p.1307-1307

2008

Volltextzugriff (PDF)

Biases in cost measurement for economic evaluation studies in health care

Health economics, 1996-11, Vol.5 (6), p.525-529

1996

Volltextzugriff (PDF)

Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies

Blood, 2009-11, Vol.114 (22), p.2486-2486

2009

Volltextzugriff (PDF)

Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer

Current medical research and opinion, 2014-06, Vol.30 (6), p.1007-1016

2014

Volltextzugriff (PDF)

Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States

American journal of hematology, 2008-04, Vol.83 (4), p.263-270

2008

Volltextzugriff (PDF)

Rivastigmine for alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications

Clinical therapeutics, 2000-12, Vol.22 (12), p.1549-1561

2000

Volltextzugriff (PDF)

Treatment interruptions and non-adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenous leukaemia

PharmacoEconomics, 2007-01, Vol.25 (6), p.481-496

2007

Volltextzugriff (PDF)

Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients : US healthcare system perspective

PharmacoEconomics, 2007-01, Vol.25 (4), p.329-342

2007

Volltextzugriff (PDF)

Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial

Acta haematologica, 2010-01, Vol.123 (4), p.220-225

2010

Volltextzugriff (PDF)

Research and innovation in the development of everolimus for oncology

Expert opinion on drug discovery, 2011-03, Vol.6 (3), p.323-338

2011

Volltextzugriff (PDF)

An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial

Advances in therapy, 2010-08, Vol.27 (8), p.533-546

2010

Volltextzugriff (PDF)

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial

Acta haematologica, 2008, Vol.119 (3), p.133-141

2008

Volltextzugriff (PDF)

A comparative review of pharmacoeconomic guidelines

PharmacoEconomics, 1995-09, Vol.8 (3), p.182-189

1995

Volltextzugriff (PDF)

An economic evaluation of finasteride for treatment of benign prostatic hyperplasia

PharmacoEconomics, 1996-05, Vol.9 (5), p.443-454

1996

Volltextzugriff (PDF)

Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development

The cancer journal (Sudbury, Mass.), 2009-09, Vol.15 (5), p.386

2009

Volltextzugriff (PDF)

Progression-Free Survival: Gaining on Overall Survival as a Gold Standard and AcceleratingDrug Development

The cancer journal (Sudbury, Mass.), 2009-09, Vol.15 (5), p.386-394

2009

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Adult
(10)
Female
(10)
Male
(10)
Middle Aged
(10)
Pharmacology & Pharmacy
(10)
Adolescent
(9)
Biological And Medical Sciences
(9)
Health Care Sciences & Services
(9)
Health Policy & Services
(9)
Medical Sciences
(9)
Business & Economics
(8)
Economics
(8)
Social Sciences
(8)
Treatment Outcome
(8)
Child
(7)
Health Technology Assessment
(7)
Iron Chelating Agents - Therapeutic Use
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical and economic burden of infused iron chelation therapy in the United States

Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload

Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review

Use of economic evaluation guidelines: 2 years' experience in Canada

The impact of iron overload and its treatment on quality of life: results from a literature review

Satisfaction and Adherence in Patients with Iron Overload Receiving Iron Chelation Therapy as Assessed by a Newly Developed Patient Instrument

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia

Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib

Satisfaction and Adherence Significantly Improves in Patients with β-Thalassemia and Myelodysplastic Syndromes Treated with Deferasirox (Exjade®)

Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade®)

Biases in cost measurement for economic evaluation studies in health care

Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies

Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer

Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States

Rivastigmine for alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications

Treatment interruptions and non-adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenous leukaemia

Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients : US healthcare system perspective

Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial

Research and innovation in the development of everolimus for oncology

An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial

A comparative review of pharmacoeconomic guidelines

An economic evaluation of finasteride for treatment of benign prostatic hyperplasia

Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development

Progression-Free Survival: Gaining on Overall Survival as a Gold Standard and AcceleratingDrug Development

Suchergebnisse filtern